EGFR and breast carcinoma: Upon intravenous injections, the construct, equipped with the anti-epidermal growth factor receptor (EGFR) CL4 aptamer [41, 58, 59] as a specific ligand for tumor-targeting, resulted able to drastically inhibit breast cancer growth, with nearly undetectable toxicity and immune responses in mice.